ACADIA Pharmaceuticals joins Russell 1000 Index

ACADIA Pharmaceuticals, a biopharmaceutical company that is dedicated to creating and selling novel medicines to resolve the unmet medical needs of central nervous system disorders, recently joined the Russell 1000 Index.

ACADIA officially became part of the index on June 27.

The Russell 1000 Index, a subset of the Russell 3000 Index, contains an estimated 1,000 of the biggest securities. Their size is determined by combining their market cap with their current index membership.

All of the Russell indices are recalibrated each year. This guarantees that the index accounts for new, growing equities each year. The index provides a measurement of how the national large-cap segment performs each year.

The Russell Index, wholly owned by London Stock Exchange Group, has a crucial role as a worldwide index leader as well as data provider. It calculates and measures thousands of various indexes that are designed to benchmark and measure markets as well as asset classes in over 70 countries. This means that the Russell Index includes 98 percent of the world’s investable market. The index offers innovative analytics, benchmarking, and data solutions for countless investors around the world.